Jan 28, 2015 by Brian Orelli, PhDNatus Medical Inc. Serves Up a New Business ModelThe medical device maker moves further into testing services.
Jan 22, 2015 by Brian Orelli, PhDDon't Fret About Intuitive Surgical, Inc.'s Lower Gross MarginsEarnings fall despite an increase in revenue, but investors shouldn't panic.
Jan 21, 2015 by Brian Orelli, PhDIntuitive Surgical Inc. Slices Revenue and Earnings ReleasesIntuitive Surgical released four-quarter revenue last week, but we'll get the earnings number on Thursday.
Jan 21, 2015 by Brian Orelli, PhDState of the Union Address Investing Idea: Precision MedicineThere are plenty of companies developing precision medicine drugs already, and investors would be wise to watch key players.
Jan 21, 2015 by Brian Orelli, PhDMannKind Corporation on Track for Afrezza LaunchMannKind partner Sanofi is close to launching its inhaled insulin Afrezza, but will doctors prescribe it?
Jan 16, 2015 by Brian Orelli, PhDVertex Pharmaceuticals Going to Get Fat on Cystic Fibrosis PieDifferent drugs for different cystic fibrosis patients.
Jan 14, 2015 by Brian Orelli, PhDGilead Sciences, Inc. Is No Longer Just an HIV CompanyHIV drugs now make up less than half of Gilead Sciences' revenue.
Jan 13, 2015 by Brian Orelli, PhDCelgene Corporation's Future: Everything You Need to Know in 5 SlidesCelgene presents at the JP Morgan Healthcare Conference.
Jan 13, 2015 by Brian Orelli, PhDLess Mann in MannKind CorporationAlfred Mann retires as CEO, but investors needn't worry.
Jan 10, 2015 by Brian Orelli, PhDThe Dark Secret in the AbbVie-Gilead Sciences Hepatitis C Drug WarWe don't know the true price of AbbVie's Viekira Pak and Gilead's Harvoni.
Jan 10, 2015 by Brian Orelli, PhDCancel JPMorgan! Plenty of Pre-Conference Data and Deals to DigestThe week before JPMorgan Healthcare conference brought a plethora of deals and data.
Jan 8, 2015 by Brian Orelli, PhDArena Pharmaceuticals Inc.'s Phase 1 Data is Worth $550 Million!?Investors bid up Arena Pharmaceuticals 76% after the biotech releases positive phase 1 data for APD334.
Dec 31, 2014 by Brian Orelli, PhDThe Market for This Drug Just Got 19% Bigger, but You Haven't Seen Anything YetVertex Pharmaceuticals Incorporated gets an expanded approval for its cystic fibrosis drug Kalydeco.
Dec 31, 2014 by Brian Orelli, PhDCan MannKind Corporation Stock Soar in 2015?While expectations for Afrezza are somewhat low, MannKind's marketing partner, Sanofi, still might have trouble meeting them.
Dec 29, 2014 by Brian Orelli, PhDGilead Sciences, Inc. Can't Do It AloneGilead Sciences and Johnson & Johnson team up to develop HIV pills.
Dec 27, 2014 by Brian Orelli, PhDThe Newest FDA-Approved Obesity Drug Is Also the OldestNovo Nordisk gains FDA approval for Saxenda, which is already approved as an obesity treatment called Victoza.
Dec 24, 2014 by Brian Orelli, PhDThis Cancer Drug War Is Just Getting StartedThe FDA approves Bristol-Myers Squibb's Opdivo, pitting it against Merck's Keytruda that was approved earlier this year.
Dec 23, 2014 by Brian Orelli, PhDAbbVie Inc. Throws First Punch in Hep C Price War With Gilead Sciences, Inc.Express Scripts makes AbbVie's Viekira Pak its exclusive hepatitis C drug, excluding Gilead's Harvoni.
Dec 21, 2014 by Brian Orelli, PhDNew Obesity Drug Available SoonOrexigen is close to getting Mysimba on the market in Europe.
Dec 21, 2014 by Brian Orelli, PhDGilead Sciences, Inc. Gets Some Competition (but Not Really)AbbVie gains FDA approval for Viekia Pak; but without a discount, it's hard to see it competing with Harvoni.
